BRAF and neoplasm: Recently, a homozygous deletion of CDKN2A/B, corresponding to the loss of 9q21.3, was found as a rather distinctive molecular feature of PXA, regardless of tumor grade or BRAF mutation (Vaubel et al., 2018).